2021-06-28T10:48:40-05:00 2020-09-30 366055558 GRANT THORNTON LLP 757 THIRD AVE 3RD FLOOR NEW YORK NY 100172013 990 2019-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH FOUN 2128061600 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 BRADLEY JENSEN ASSISTANT TREASURER/CFO 2128061600 2021-06-28 1 SCOTT THOMPSETT P00741490 2125990100 2019 2022-09-23 18:48:47Z AIDS RESEARCH OR AMFAR KEVIN FROST 120 WALL STREET 13TH FLOOR NEW YORK NY 10005 45304972 0 X WWW.AMFAR.ORG X 1983 NY AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. (SEE SCHEDULE O). 13 13 90 0 0 0 40275703 21630486 0 0 2262943 3193491 -11197256 -3481467 31341390 21342510 10109752 5897226 0 0 11146319 11392441 747847 469617 4526560 12968286 11082612 34972204 28841896 -3630814 -7499386 64157103 54739518 14672542 13093624 49484561 41645894 X SEE SCHEDULE O. 0 0 11724295 4168242 0 RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEDULE O. AMFAR FELLOWSHIPS ALLOW TALENTED YOUNG RESEARCHERS TO CONDUCT ORIGINAL INVESTIGATIONS UNDER THE GUIDANCE OF EXPERIENCED SCIENTISTS, HELPING TO ENSURE THE LONG-TERM VITALITY OF AIDS RESEARCH.NEW GRANTS AND FELLOWSHIPSGRANTS AND FELLOWSHIPS ARE AWARDED THROUGH A RIGOROUS PROCESS OF PEER REVIEW BY A TEAM OF INDEPENDENT HIV/AIDS EXPERTS DRAWN LARGELY FROM THE VOLUNTEER SCIENTISTS ON AMFAR'S SCIENTIFIC ADVISORY COMMITTEE. GUIDED BY ITS SCIENTIFIC ADVISORS AND WITH THE APPROVAL OF ITS BOARD OF TRUSTEES, AMFAR PURSUES A STRATEGIC RESEARCH PLAN THAT FOCUSES ON THE PURSUIT OF A CURE FOR HIV. COUNTDOWN TO A CURE FOR AIDSIN 2015, AMFAR ANNOUNCED AN INVESTMENT STRATEGY OF UP TO $100 MILLION TO SUPPORT ITS COUNTDOWN TO A CURE FOR AIDS INITIATIVE, WHICH WAS AIMED AT DEVELOPING THE SCIENTIFIC BASIS FOR A CURE BY THE END OF 2020. THE STRATEGY REPRESENTS AN UNPRECEDENTED EXPANSION OF AMFAR'S GRANT MAKING AND WAS DESIGNED TO PROVIDE SUPPORT TO ANY SCIENTIST OR TEAM OF INVESTIGATORS FOR ANY RESEARCH IDEA WITH THE POTENTIAL TO ADVANCE THE SEARCH FOR A CURE, AT ANY STAGE OF ITS DEVELOPMENT. IT WAS STRUCTURED TO PROVIDE SUSTAINED SUPPORT FOR A WIDE RANGE OF STUDIES THAT ADVANCE BOTH EMERGING AND ESTABLISHED IDEAS. THE STRATEGY COMPRISED THE FOLLOWING COMPONENTS:AMFAR INSTITUTE FOR HIV CURE RESEARCHESTABLISHED IN 2015 WITH A $20 MILLION GRANT OVER FIVE YEARS TO THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE INSTITUTE IS THE CORNERSTONE OF AMFAR'S CURE RESEARCH. INNOVATION GRANTS THESE TWO-YEAR AWARDS OF UP TO $200,000 EACH ENABLE RESEARCHERS TO TEST INNOVATIVE IDEAS SUPPORTED BY LIMITED PRELIMINARY DATA.IMPACT GRANTSTHESE GRANTS OF UP TO $2 MILLION EACH OVER FOUR YEARS SUPPORT THE IN-DEPTH DEVELOPMENT OF CONCEPTS ALREADY UNDERPINNED BY PRELIMINARY DATA SHOWING GENUINE POTENTIAL FOR ACHIEVING A CURE.INVESTMENT GRANTSAIMED AT RECRUITING THE EXPERIENCE AND EXPERTISE OF SCIENTISTS FROM OUTSIDE THE FIELD OF HIV, THESE $1 MILLION GRANTS ARE AWARDED OVER A FOUR-YEAR PERIOD. GRANTEES MAY HAVE EXPERTISE IN FIELDS SUCH AS CANCER, NEUROSCIENCE, OR INFLAMMATORY DISEASE THAT CAN DIRECTLY INFORM EFFORTS TO CURE HIV. ARCHELAUNCHED IN 2010, THE AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION, OR ARCHE, SUPPORTS COLLABORATIVE TEAMS OF SCIENTISTS IN THE U.S. AND AROUND THE WORLD WORKING ON A RANGE OF HIV CURE STRATEGIES.MAGNET GRANTSUNITING DATA SCIENTISTS WITH HIV RESEARCHERS, THESE ONE-YEAR GRANTS OF UP TO $150,000 ARE HARNESSING ADVANCES IN MACHINE LEARNING ALGORITHMS TO FIND PATTERNS IN DATASETS THAT MAY ADVANCE OUR SEARCH FOR A CURE.SYNERGY GRANTSTHESE GRANTS CAPITALIZE ON UNFORESEEN POSSIBILITIES FOR COLLABORATION AND ENABLE US TO ADD NEW STUDY ARMS ONTO EXISTING AMFAR GRANTS.OPPORTUNITY FUNDTHIS FUNDING MECHANISM ENABLES AMFAR TO RESPOND QUICKLY TO EMERGING AND UNFORESEEN RESEARCH OPPORTUNITIES.SINCE LAUNCHING THE COUNTDOWN TO A CURE FOR AIDS INITIATIVE, AMFAR HAS AWARDED 87 COUNTDOWN GRANTS TOTALING MORE THAN $50 MILLION TO SUPPORT RESEARCH CONDUCTED BY 305 SCIENTISTS WORKING AT 103 INSTITUTIONS IN 16 COUNTRIES.DUE TO THE COVID-19 PANDEMIC, IN MARCH 2020 AMFAR TEMPORARILY PAUSED ITS ONGOING RESEARCH GRANTS WITH THE EXCEPTION OF ONE GRANT FUNDED BY THE FAIR FOUNDATION. THE PAUSE ENDED ON JULY 1, 2020, FOR A CLINICAL TRIAL AT THE AMFAR INSTITUTE FOR HIV CURE RESEARCH IN SAN FRANCISCO, AND OCTOBER 1 FOR OTHER PAUSED RESEARCH. GRANTS SUPPORTED THROUGH THE NEWLY FORMED AMFAR FUND TO FIGHT COVID-19 (SEE BELOW) WERE NOT IMPACTED.MAGNET GRANTSIN A NEW ROUND OF GRANTS, AMFAR BROUGHT MACHINE LEARNING TO BEAR TO SEARCH FOR ANSWERS WITHIN THE VAST TROVE OF DATA HIV RESEARCHERS HAVE AMASSED OVER THE PAST DECADE. ALREADY A CRITICAL COMPONENT OF THE SUCCESS OF PRECISION MEDICINE, MACHINE LEARNING IS ABLE TO IDENTIFY PATTERNS IN HEALTH AND DISEASE THAT WE WOULDN'T KNOW TO LOOK FOR. IN FEBRUARY 2020, AMFAR AWARDED GRANTS TOTALING APPROXIMATELY $600,000 TO RESEARCH TEAMS IN THE U.S., AUSTRALIA, AND BRAZIL. THROUGH THESE MAGNET GRANTS, WHICH UNITE DATA SCIENTISTS WITH HIV RESEARCHERS, AMFAR HOPES TO USE ADVANCES IN MACHINE LEARNING ALGORITHMS TO FIND PATTERNS IN DATASETS THAT MAY ADVANCE OUR SEARCH FOR A CURE. GRANTEES INCLUDE DR. HILLEL HAIM, AN HIV SCIENTIST AT THE UNIVERSITY OF IOWA. DR. HAIM IS COLLABORATING WITH MACHINE LEARNING SPECIALIST DR. GUIPING HU AND NETWORK SYSTEMS ANALYST DR. GRANT BROWN TO IDENTIFY HIV MUTATION NETWORKS IN MORE THAN 350 PATIENTS. IF THE RESEARCHERS CAN PREDICT HOW HIV WILL EVOLVE IN EACH PATIENT, THEY CAN TAILOR ANTIBODY INFUSION COCKTAILS TO TARGET FUTURE HIV STRAINS AND THEREBY IMPROVE ANTIBODY-BASED CURATIVE INTERVENTIONS. THE SIZE OF THE HIV RESERVOIR CHANGES THROUGHOUT THE LIFESPAN OF A PERSON LIVING WITH HIV. THE RESERVOIR MAY EXPAND WHEN INFECTED T CELLS GROW IN NUMBER TO FIGHT INVADING PATHOGENS. IDENTIFYING HOW TO LIMIT THAT EXPANSION IN RESERVOIR CELLS WHILE MAINTAINING NORMAL EXPANSION IN UNINFECTED T CELLS WOULD BE AN IMPORTANT STEP TOWARD A CURE. DR. YA-CHI HO HAS COLLECTED VAST AMOUNTS OF DATA ON THE ACTIVITY OF OVER 133,000 T CELLS, INCLUDING RARE RESERVOIR CELLS, ACROSS SEVEN PEOPLE LIVING WITH HIV. WITH THE HELP OF BIOINFORMATICIAN DR. DAVID VAN DIJK, THE TEAM IS BUILDING MACHINE-LEARNING TOOLS TO IDENTIFY MEDIATORS OF T CELL EXPANSION THAT AFFECT RESERVOIR CELLS SPECIFICALLY. HIV HAS AN IMPRESSIVE ARSENAL OF DEFENSES AGAINST THE HUMAN IMMUNE SYSTEM'S BEST EFFORTS TO DESTROY THOSE VIRUSES THAT MATTER, NAMELY THE ONES WITH AN INTACT GENETIC SEQUENCE. DR. BRAD JONES POSITS THAT HE HAS DISCOVERED YET ANOTHER MECHANISM THE VIRUS USES TO PROTECT INFECTED CELLS. COLLABORATING WITH DATA SCIENTISTS DRS. DORON BETEL AND FRIEDERIKE DUNDAR, DR. JONES AIMS TO IDENTIFY, USING PUBLIC AND PRIVATE DATASETS, DIFFERENCES BETWEEN RESERVOIR CELLS THAT SURVIVED IMMUNE ATTACK VERSUS THOSE THAT WERE SUSCEPTIBLE. THEN THE RESEARCHERS WILL ANALYZE CANCER DATASETS TO DETERMINE WHETHER THOSE PROTECTIVE FACTORS IDENTIFIED IN HIV ARE ALSO PRESENT IN CANCERA DISEASE THAT MAY HAVE FDA-APPROVED DRUGS TO TARGET THOSE FACTORS. BY UNDERSTANDING EXACTLY WHERE HIV INSERTS ITSELF IN OUR GENOME, RESEARCHERS CAN MAKE INFERENCES ABOUT HOW LOCATION MAY PREDICT LATENCY. DR. SHARON LEWIN, A WORLD-RENOWNED HIV CURE RESEARCHER, HAS TEAMED UP WITH DR. DANIEL CAMERON, A FORMER SOFTWARE DEVELOPER TURNED ACADEMIC BIOINFORMATICIAN, TO DEVELOP A DATA SCIENCE MAPPING PIPELINE TO CHART THE HARD-TO-REACH AREAS OF OUR GENOME. USING OVER 600GB OF CLOUD COMPUTING MEMORY AND MINING 30 PUBLIC AND PRIVATE DATASETS, THE RESEARCHERS AIM TO GAIN A MORE COMPLETE UNDERSTANDING OF WHAT INSERTION SITE MEANS FOR HIV LATENCYAND ULTIMATELY CURE. ELITE CONTROLLERS (ECS) ARE ABLE TO CONTROL THEIR HIV INFECTION WITHOUT THE NEED FOR ANTIRETROVIRAL THERAPY. RESEARCHERS HAVE BEEN STUDYING ECS FOR DECADES BECAUSE IT IS HOPED THAT BY LEARNING HOW THEY ACHIEVE CONTROL COULD POINT THE WAY TO INDUCING CONTROL IN THE MAJORITY OF PEOPLE LIVING WITH HIV WHO ARE NOT ECS. DR. SIMONE GONALVES AIMS TO COMBINE DATASETS FROM THOSE DECADES OF EC RESEARCH WITH HER OWN DATA ON METABOLIC ACTIVITY IN A COHORT OF ECS. BY FORMING A COLLABORATION WITH DATA SCIENTIST DR. LUIZ GUSTAVO GARDINASSI, DR. GONALVES HOPES TO GLEAN NEW INSIGHTS FROM ARCHIVED DATA INTO MECHANISMS OF VIRAL CONTROL. THIS GRANT WAS UNDERWRITTEN IN ITS ENTIRETY BY THE FAIR FOUNDATION.SYNERGY GRANTSIN FEBRUARY 2020, AMFAR AWARDED $50,000 TO DR. JONATHAN LI OF THE BRIGHAM AND WOMEN'S HOSPITAL IN BOSTON. IN 2019, AMFAR LAUNCHED PROJECT PTC, THE LARGEST STUDY TO DATE AIMED AT DISCOVERING THE UNDERPINNINGS OF POST-TREATMENT CONTROLVIRAL CONTROL IN THE ABSENCE OF ANTIRETROVIRAL THERAPY (ART). LED BY DR. LI, ONE OF THE WORLD'S LEADING PTC RESEARCHERS, THE TEAM HAS BEEN USING CUTTING-EDGE TOOLS TO EXPLORE IMMUNE CONTROL AND VIRAL DYNAMICS. THE NEW GRANT RECRUITS THE EXPERTISE OF DR. MICHAEL SEAMAN, AN EXPERT IN HIV ANTIBODY RESPONSES AT HARVARD MEDICAL SCHOOL. THIS ADDITIONAL EXPERTISE COULD HELP DETERMINE WHETHER ANTIBODIES HELP SHAPE THE ABILITY OF PTCS TO CONTROL VIRUS ONCE THEY STOP TAKING ART. DISCOVERING WHAT LEADS TO POST-TREATMENT CONTROL IN THESE RARE INDIVIDUALS COULD HELP IN DESIGNING METHODS TO ACHIEVE DURABLE ART-FREE CONTROL IN ALL PEOPLE LIVING WITH HIV. 4546419 1728984 0 TREAT ASIA: AMFAR'S TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. FOR FURTHER DETAILS, SEE SCHEDULE O. TREAT ASIA SCIENTISTS PRODUCED 33 PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS IN 2020. INTERNATIONAL AIDS DATABASETREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)TREAT ASIA PIONEERED THE REGION'S FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH NOW INCLUDES ANONYMOUS DATA FROM NEARLY 10,000 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES. THE INFORMATION GATHERED IN THE DATABASE INFORMS THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPS DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. TAHOD LOW-INTENSITY TRANSFER LAUNCHED IN 2014, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINS DATA FROM OVER 37,000 HIV-POSITIVE PATIENTS ACROSS TEN TREAT ASIA NETWORK SITES. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF HIV-INFECTED PATIENTS WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES. TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 7,400 CHILDREN AND ADOLESCENTS AT 17 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM.INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCHIN 2019, THE U.S. NATIONAL INSTITUTES OF HEALTH AWARDED A FIVE-YEAR, $1.4 MILLION GRANT TO TREAT ASIA AND COLUMBIA UNIVERSITY TO ESTABLISH AN INNOVATIVE PLATFORM FOR INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN THE ASIA-PACIFIC REGION. THE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG, PROFESSOR OF CLINICAL PSYCHIATRY AT COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE THE QUALITY OF CLINICAL CARE FOR PEOPLE LIVING WITH HIV. THE PROGRAM IS NESTED WITHIN THE IEDEA (SEE ABOVE) ASIA-PACIFIC REGIONAL RESEARCH NETWORK THAT TREAT ASIA DIRECTS. CHIMERA CREATES THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND WILL BUILD ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC.IN FEBRUARY 2020, A WORKSHOP FOR CHIMERA FELLOWS WAS HELD IN BANGKOK, COVERING IMPLEMENTATION SCIENCE FRAMEWORKS AND STUDY DESIGNS, INFORMATICS FOR RESEARCH AND PUBLIC HEALTH, AND THE RESPONSIBLE CONDUCT OF RESEARCH. FELLOWS ALSO MET WITH TREAT ASIA AND FACULTY TO DISCUSS THEIR PILOT RESEARCH PROPOSALS.THE COVID-19 PANDEMICIN APRIL 2020, TREAT ASIA LED THE SUBMISSION OF A LETTER TO THE REGIONAL DIRECTORS OF WORLD HEALTH ORGANIZATION (WHO) SOUTH-EAST ASIA AND WESTERN-PACIFIC REGIONAL OFFICES. SIGNED BY 32 REGIONAL AND NATIONAL CIVIL SOCIETY ORGANIZATIONS, THE LETTER CALLED FOR WHO TO PLAY A GREATER ROLE IN ENSURING CONTINUITY OF HIV-RELATED HEALTHCARE SERVICES DURING THE COVID-19 PUBLIC HEALTH EMERGENCY IN THE ASIA-PACIFIC. TREAT ASIA IS COLLABORATING WITH THE INSTITUTE OF HIV RESEARCH AND INNOVATION (IHRI), THAI RED CROSS AIDS RESEARCH CENTER (TRC-ARC) LABORATORY, AND THE NIH VACCINE RESEARCH CENTER TO CONDUCT SARS-COV-2 SEROLOGIC ASSAYS OF THAI ADULTS TAKING AND NOT TAKING ANTIRETROVIRAL DRUGS FOR PRE-EXPOSURE PROPHYLAXIS AND TREATMENT OF HIV. IN SEPTEMBER 2020, MORE THAN 1,800 SAMPLES WERE SENT TO THE NATIONAL INSTITUTES OF HEALTH.THROUGHOUT THE YEAR, TREAT ASIA PARTICIPATED IN VARIOUS MEETINGS HELD VIRTUALLY WITH ORGANIZATIONS AND COMMUNITY MEMBERS FROM COUNTRIES THROUGHOUT THE ASIA-PACIFIC REGION TO NAVIGATE THE IMPACTS OF COVID-19 ON CRITICAL HIV AND HEPATITIS SERVICES AND INITIATIVES.EMPOWERING YOUTH ADVOCATESIN AUGUST 2019, TREAT ASIA'S YOUTH ACATAASIA COMMUNITY FOR AIDS TREATMENT AND ADVOCACYHELD ITS SEVENTH AND FINAL WORKSHOP IN BANGKOK FOR YOUTH ACATA CLASS II MEMBERS. THE WORKSHOP PROVIDED AN UPDATE ON HIV SCIENCE AND RESEARCH, AND ASSESSED THE EFFECTIVENESS AND OUTCOMES OF THE CLASS II PROGRAM AND PARTICIPANT SMALL GRANTS PROJECTS. THREE CLASS I PARTICIPANTS SHARED THEIR EXPERIENCE AND PERSPECTIVES AS GRADUATES OF THE PROGRAM.HELPING ADOLESCENTS TRANSITION TO ADULT CAREMORE THAN ONE IN FOUR NEW HIV INFECTIONS IN THE ASIA-PACIFIC OCCUR IN YOUNG PEOPLE AGED 1524 YEARS. CONTINUING ITS COMMITMENT TO HELPING ADOLESCENTS TRANSITION TO ADULT CARE, IN 2019 TREAT ASIA INITIATED PLANS FOR A STUDY OF ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV. A TOTAL OF 75 HIV-DISCLOSED ADOLESCENTS WITH HIV WILL BE ENROLLED FROM THREE PARTICIPATING SITES IN THAILAND AND THE PHILIPPINES FOR INITIAL AND 12-MONTH FOLLOW-UP ASSESSMENTS. CRITICAL OUTCOMES INCLUDING VIRAL SUPPRESSION, TREATMENT ADHERENCE, PREGNANCY, AND MORTALITY WILL BE ASSESSED. ENROLLMENT IS EXPECTED IN EARLY 2021. PUBLICATIONSIN 2020 TREAT ASIA CONTINUED TO PUBLISH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC AS A WHOLE. THE ARTICLES AND EDUCATIONAL PIECES APPEAR ON TREAT ASIA'S WEBSITE, WWW.TREATASIA.ORG.19TH ANNUAL NETWORK MEETINGTHE 2019 TREAT ASIA ANNUAL NETWORK MEETING WAS HELD IN OCTOBER 2019 IN BANGKOK, THAILAND, WHERE ADULT AND PEDIATRIC INVESTIGATORS, DONORS, AND PROGRAM PARTNERS GATHERED TO REVIEW PROGRESS ON THE NETWORK'S RESEARCH AGENDA, HEAR ABOUT REGIONAL HIV-RELATED POLICY PRIORITIES, AND PLAN FOR FUTURE INITIATIVES. AIDS 2020 AND OTHER CONFERENCESTREAT ASIA STAFF AND NETWORK INVESTIGATORS ATTENDED AND PRESENTED AT SEVERAL REGIONAL AND INTERNATIONAL CONFERENCES ON HIV-RELATED ISSUES. TREAT ASIA HAD A STRONG PRESENCE AT THE 23RD INTERNATIONAL AIDS SOCIETY CONFERENCE (AIDS 2020) HELD VIRTUALLY IN JULY. TREAT ASIA DIRECTOR DR. ANNETTE SOHN MODERATED A PRIME SESSION Q&A ON PEDIATRIC HIV ALONG WITH MARTINA PENAZZATO OF THE WORLD HEALTH ORGANIZATION. DR. SOHN ALSO SPOKE AT A WORKSHOP ADDRESSING THE ESSENTIAL SKILL FOR EARLY-CAREER HIV RESEARCHERS OF WRITING AND SUCCESSFULLY SUBMITTING SCIENTIFIC PAPERS TO PEER-REVIEWED JOURNALS. NUMEROUS TREAT ASIA PARTNER INVESTIGATORS AND AFFILIATES ALSO GAVE POSTER PRESENTATIONS AT THE CONFERENCE.TREAT ASIA ALSO PARTICIPATED IN THE FIFTH ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC), HELD VIRTUALLY IN OCTOBER 2020. APACC IS A REGIONAL-LEVEL HIV RESEARCH CONFERENCE THAT PROVIDES OPPORTUNITIES FOR LOCAL CLINICIANS, STUDENTS, AND RESEARCHERS TO SUBMIT ABSTRACTS FOR PRESENTATION. 3662313 0 0 PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEDULE O. THE COVID-19 PANDEMICWHEN THE COVID-19 CRISIS EMERGED IN EARLY 2020, AMFAR DEDICATED A SECTION OF ITS WEBSITE TO INFORMATION ON THE CORONAVIRUS AND THE INTERSECTION OF HIV AND COVID-19 IN PARTICULAR. THE SECTION FEATURED RESOURCES FOR PEOPLE LIVING WITH HIV AND NEWS OF THE LATEST STUDIES AS MORE AND MORE DATA EMERGED. AUDIOVISUAL CONTENT INCLUDED A VIDEO ANNOUNCEMENT OF THE LAUNCH OF THE AMFAR FUND TO FIGHT COVID-19 AND A SERIES OF INTERVIEWS FEATURING AMFAR VP AND DIRECTOR OF RESEARCH DR. ROWENA JOHNSTON AND AMFAR GRANTEES WHO HAD QUICKLY PIVOTED TO RESEARCH ON COVID-19. THESE INFORMATIVE INTERVIEWS COVERED TOPICS SUCH AS TESTING, VACCINE DEVELOPMENT, EXPERIMENTAL TREATMENTS, AND COVID IN CHILDREN, AND GARNERED TENS OF THOUSANDS OF VIEWS. PUBLIC INFORMATION ALSO ASSISTED IN THE PRODUCTION OF INNOVATIVE VIRTUAL BENEFIT EVENTS INCLUDING CR RUNWAY WITH AMFAR AGAINST COVID-19 IN MAY 2020 AND FROM THE STUDIO, AN ONLINE ART AUCTION IN PARTNERSHIP WITH CHRISTIE'S IN JULY 2020.EDUCATIONAL MATERIALS AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND ELECTRONIC FORMATS, INCLUDING ITS NEWSLETTER INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO MORE THAN 40,000 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER DISTRIBUTED TO APPROXIMATELY 10,000 PEOPLE. THE FOUNDATION'S WEBSITES WWW.AMFAR.ORG AND WWW.CURECOUNTDOWN.ORG FEATURE NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITES ATTRACT A COMBINED AVERAGE OF 46,000 VISITORS PER MONTH. AMFAR ALSO CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.EPIC VOICESAMFAR'S EPIC VOICES, AN ONLINE VIDEO SERIES THAT AIMS TO REENERGIZE THE RESPONSE TO HIV AMONG MILLENNIAL AND LGBTQ COMMUNITIES CONTINUED TO GENERATE SIGNIFICANT ENGAGEMENT IN 2020. IN AUGUST 2020 A TEN-EPISODE INSTAGRAM IGTV SERIES BEGAN THAT FEATURED THE VIDEOS. THE SERIES RECEIVED MORE THAN 7,500 VIEWS. LAUNCHED IN 2017, THE GOALS OF THE CAMPAIGN ARE TO: RENEW AWARENESS OF THE PERSISTENT THREAT OF HIV, UNDERSCORE THE URGENT NEED TO SUPPORT HIV RESEARCH, AND SUPPORT AMFAR'S LEADERSHIP IN THE SEARCH FOR A CURE. AMFAR SPOKE TO HIV ACTIVISTS ACROSS THE COUNTRY AND ASKED THEM TO SHARE THEIR UNIQUE JOURNEYS, THEIR INSIGHTS ON LIVING WITH HIV, AND THE BOLD STEPS THEY HAVE TAKEN IN THE FIGHT AGAINST THE EPIDEMIC.SOCIAL MEDIAAMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. THE FOUNDATION REGULARLY ADDS CONTENT TO ITS FACEBOOK PAGE, LIVE TWEETS FROM EVENTS, AND POSTS IMAGES ON INSTAGRAM FROM FUNDRAISING AND PROGRAM EVENTS. AMFAR HAS OVER 76,000 LIKES ON FACEBOOK, MORE THAN 43,000 TWITTER FOLLOWERS, AND 159,000 INSTAGRAM FOLLOWERS. MEDIA OUTREACHIN FY2020, AMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFARMANY OF WHICH INCLUDED INTERVIEWS WITH STAFFWERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING THE NEW YORK TIMES, THE WALL STREET JOURNAL, THE WASHINGTON POST, FAST COMPANY, THE ATLANTIC, VICE, HUFFPOST, BUSINESS INSIDER, U.S. NEWS & WORLD REPORT, VOX, VANITY FAIR, NEW YORK MAGAZINE, PEOPLE, GIZMODO, THE VERGE, THE ADVOCATE, POLITICO, THE HILL, REUTERS, ASSOCIATED PRESS, CBS NEWS, BBC NEWS, CNN, NPR, MSNBC, ABC NEWS, AND NBC NEWS.CELEBRITY SUPPORT AMFAR'S PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATION'S MISSION. SUPPORT OF AMFAR BY PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFAR'S FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD.CELEBRITY SUPPORTERS INCLUDED JAMES CORDEN, TOM FORD, CHEYENNE JACKSON, PARIS JACKSON, HEIDI KLUM, KATY PERRY, JULIA ROBERTS, ALAN CUMMING, CHRISTINA AGUILERA, GWYNETH PALTROW, BOBBY BERK, AMELIA GRAY HAMLIN, DELILAH BELLE HAMLIN, LUKA SABBAT, NICOLE SCHERZINGER, CAROLINE VREELAND, GLORIA GAYNOR, CHARLIE PUTH, LILY ALDRIDGE, ADRIEN BRODY, ANDY COHEN, DIPLO, PADMA LAKSHMI, BILLY PORTER, ZAC POSEN, LAID RIBEIRO, COCO ROCHA, CARINE ROITFELD, AMBER VALLETTA, VIRGIL ABLOH, ALESSANDRA AMBROSIO, HAILEY BIEBER, ABBY CHAMPION, PETER DUNDAS, ASHLEY GRAHAM, WINNIE HARLOW, KIM KARDASHIAN WEST, MIRANDA KERR, KARLIE KLOSS, KAROLINA KURKOVA, ADRIANA LIMA, BRANDON MAXWELL, STELLA MAXWELL, OLIVIER ROUSTEING, JASMINE SANDERS, SHANINA SHAIK, IRINA SHAYK, JOAN SMALLS, LARA STONE, JASMINE TOOKES, DIANE VON FRSTENBERG, AND ALEXANDER WANG. 1776060 0 0 PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH AND GLOBAL HIV/AIDS PROGRAMS, EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, ADVOCATE HARM REDUCTION POLICIES AIMED AT REDUCING THE SPREAD OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. ENDING THE DOMESTIC HIV EPIDEMICDURING THE 2019 STATE OF THE UNION, PRESIDENT TRUMP ANNOUNCED A PLAN TO END HIV TRANSMISSIONS IN THE U.S. BY 2030. THE ENDING THE HIV EPIDEMIC INITIATIVE (EHE) AIMS TO REDUCE HIV INFECTIONS BY 75% IN FIVE YEARS, AND BY 90% IN TEN YEARS. IN 2019, AMFAR LAUNCHED A FREE INTERACTIVE DATABASE (EHE.AMFAR.ORG) TO HELP POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS UNDERSTAND THE OPPORTUNITIES AND CHALLENGES ACROSS EHE JURISDICTIONS. THE EHE DATABASE INCLUDES DEMOGRAPHIC, POLICY, AND SERVICE PROVIDER INFORMATION, AND EPIDEMIOLOGICAL INDICATORS.IN OCTOBER 2019, AMFAR PUBLISHED CONTEXT MATTERS: ENDING THE HIV EPIDEMIC AMONG LATINX, THE FIRST IN A SERIES OF INFOGRAPHICS OUTLINING DISPARITIES IN THE IMPACTS OF THE AIDS EPIDEMIC. THIS INFOGRAPHIC SHOWED HOW LACK OF ACCESS TO HEALTHCARE ALONG WITH THE TRUMP ADMINISTRATION'S ANTI-IMMIGRANT RHETORIC AND POLICIES MAKE IT UNLIKELY THAT THE EHE WILL SUCCEED. IN FEBRUARY 2020, AMFAR PUBLISHED A SECOND INFOGRAPHIC DEPICTING THE STARK RACIAL DISPARITIES IN THE EPIDEMIOLOGY OF HIV AND ACCESS TO CARE IN THE U.S., AND HIGHLIGHTING THE FACTORS THAT ARE HELPING TO ADDRESS THESE DISPARITIES AND THOSE THAT ARE EXACERBATING THEM. IN FEBRUARY, AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY GREG MILLETT PENNED AN OP-ED FOR HEALIO'S INFECTIOUS DISEASE NEWS THAT ARGUED FOR HIV PREVENTION PROGRAMS TAILORED TO BLACK AMERICANS. THAT SAME MONTH, MILLETT PUBLISHED AN OP-ED IN THE HILL ON THE PROGRESS AND SETBACKS A YEAR INTO THE EHE.SINCE THE IMPLEMENTATION OF THE AFFORDABLE CARE ACT (ACA) IN 2010, MILLIONS OF AMERICANS INCLUDING PEOPLE LIVING WITH HIV HAVE BENEFITED FROM EXPANDED ACCESS TO HEALTHCARE. ON THE TENTH ANNIVERSARY OF THE ACA BEING SIGNED INTO LAW, IN MARCH 2020, AMFAR PUBLISHED A BROCHURE ON WHAT HAS BEEN GAINED AND WHAT COULD BE LOST DUE TO CONGRESS AND PRESIDENT TRUMP UNDERMINING THE POLICY. IN PARTICULAR, CONTEXT MATTERS: HEALTH INSURANCE IS FUNDAMENTAL TO ENDING THE HIV EPIDEMIC DREW ATTENTION TO HOW THE ACA COULD BENEFIT THE EHE INITIATIVE. THE COVID-19 PANDEMICIN MAY 2020, AMFAR RELEASED STUDY RESULTS THAT WERE AMONG THE FIRST TO QUANTITY DISPARITIES IN IMPACTS OF THE CORONAVIRUS PANDEMIC. THE STUDY REVEALED THAT DISPROPORTIONATELY BLACK COUNTIESREPRESENTING ABOUT ONE IN FIVE U.S. COUNTIESACCOUNTED FOR 52% AND 58% OF COVID-19 CASES AND DEATHS, RESPECTIVELY. IT ALSO COUNTERED THE NARRATIVE THAT UNDERLYING HEALTH CONDITIONS WERE RESPONSIBLE FOR DISPARATE RATES OF SARS-COV-2 DIAGNOSES AMONG BLACK AMERICANS. INSTEAD, SOCIAL FACTORS SUCH AS HIGH RATES OF UNINSURED AND CROWDED HOUSEHOLDS IN BLACK COUNTIES WERE RESPONSIBLE FOR GREATER RATES OF COVID-19. THE STUDY GENERATED SIGNIFICANT NATIONAL MEDIA ATTENTION. PUBLISHED IN ANNALS OF EPIDEMIOLOGY IN JULY 2020, IT HAS BEEN CITED IN MORE THAN 100 PUBLICATIONS INCLUDING THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA BY AUTHORS INCLUDING THE DIRECTORS OF THE CDC AND U.S. NATIONAL INSTITUTES OF HEALTH. ALSO IN JULY, A STUDY PUBLISHED BY A MULTI-INSTITUTIONAL TEAM LED BY RESEARCHERS AT THE GEORGE WASHINGTON UNIVERSITY FOUND THAT FACTORS LINKED TO STRUCTURAL RACISM PUT LATINO COMMUNITIES NATIONWIDE AT HIGH RISK OF COVID-19. AMFAR'S GREG MILLETT WAS SENIOR AUTHOR ON THE STUDY. THE RESEARCHERS DETAILED CONTRIBUTING FACTORS INCLUDING CROWDED HOUSING, AIR POLLUTION AND JOBS IN THE MEATPACKING AND POULTRY INDUSTRY. THE STUDY ALSO FOUND THAT LATINO COMMUNITIES IN THE MIDWEST AND NORTHEAST WERE AT PARTICULARLY HIGH RISK OF COVID-19. THE FIRST NATIONAL ANALYSIS OF COVID DEATHS AND CASES AMONG THIS GROUP, IT CONFIRMED PREVIOUS REPORTS THAT LATINOS WERE PARTICULARLY HARD HIT BY THE VIRUS. IN AUGUST, AN AMFAR STUDY SHOWED THAT DISPROPORTIONATELY WHITE COUNTIES IN THE U.S. HAD CONSISTENTLY LOWER RATES OF COVID-19 AND HIV. RESIDENTIAL SEGREGATION, STRUCTURAL RACISM, AND SOCIAL DETERMINANTS OF HEALTH WERE NOTED AS KEY FACTORS DRIVING DIAGNOSES IN NONWHITE COMMUNITIES. THE STUDY WAS PUBLISHED IN AIDS PATIENT CARE AND STDS. WITH SCHOOLS REOPENING IN SOME STATES, THE AMFAR STUDY SUGGESTED THAT COMPARATIVELY HIGHER COVID-19 DIAGNOSES IN NON-WHITE COUNTIES PLACED YOUTH AND ADULTS IN THOSE COUNTIES AT GREATER RISK FOR INFECTION.AS A COMPANION RESOURCE FOR THESE STUDIES ON DISPARITIES, AMFAR LAUNCHED A NEW DATA DASHBOARD TRACKING COVID-19 CASES AND DIAGNOSES IN U.S. COUNTIES WITH A LARGE PROPORTION OF RACIAL/ETHNIC MINORITIES.PRIOR TO COVID-19, SOUTH AFRICA FACED A WELL-DOCUMENTED EPIDEMIC OF GENDER-BASED VIOLENCE (GBV). IN AUGUST 2020, AMFAR PUBLISHED AN ISSUE BRIEF ON THE STATE OF GBV IN SOUTH AFRICA DURING THE CORONAVIRUS PANDEMIC. THE ANALYSIS FOUND SIGNIFICANT BARRIERS TO SERVICE AVAILABILITY AND CALLED FOR GOVERNMENT ACTION AND RESOURCES TO BE DIRECTED TO ENSURE RELIABLE ACCESS TO GBV SERVICES FOR THE DURATION OF COVID-19 AND BEYOND.AMFAR ALSO PUBLISHED SEVERAL OP-EDS EARLY IN THE PANDEMIC. IN FEBRUARY 2020, AMFAR SENIOR POLICY AND MEDICAL ADVISOR DR. SUSAN BLUMENTHAL PENNED AN OP-ED FOR THE HILL OUTLINING FIVE WAYS TO PREPARE FOR THE CORONAVIRUS. IN MARCH SHE WROTE FOR THE ADVOCATE ON THE ESSENTIAL LESSONS FROM THE AIDS EPIDEMIC THAT COULD BE APPLIED TO THE COVID-19 CRISIS, FOLLOWED BY TWO OP-EDS IN APRIL: ONE IN THRIVE GLOBAL ARGUED THAT YOUNG PEOPLE HELD THE KEY TO "FLATTENING THE CURVE, AND THE OTHER, FOR CNN, MADE THE CASE FOR STUDYING THE EFFECTS OF COVID ON WOMEN. HIV AND THE OPIOID EPIDEMICAMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. ITS OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) IS A FREE WEB PLATFORM DESIGNED TO SUPPORT LAWMAKERS, COMMUNITIES AND ADVOCATES IN MAKING INFORMED DECISIONS ABOUT THE OPIOID EPIDEMIC AND ITS IMPACT ON HIV AND HEPATITIS C. THE SITE IS A WINDOW INTO THE OPIOID EPIDEMIC UNFOLDING IN EVERY AMERICAN'S BACKYARD. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES.GLOBAL HEALTHIN NOVEMBER 2019, AMFAR PUBLISHED THE EXPANDED MEXICO CITY POLICY: IMPLICATIONS FOR THE GLOBAL FUND, AN ISSUE BRIEF OUTLINING THE IMPACTS OF THE "GLOBAL GAG RULE" FOR THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA. REINSTATED AND EXPANDED BY PRESIDENT TRUMP IN 2017, THE POLICY RESTRICTS NON-U.S.-BASED OR FOREIGN NGOS FROM RECEIVING AMERICAN FINANCIAL AID IF THEY PERFORM, COUNSEL ON, OR REFER FOR ABORTION, OR ADVOCATE FOR ITS LIBERALIZATION OUTSIDE OF LIMITED EXCEPTIONS.AMFAR MAINTAINS THE PEPFAR MONITORING, EVALUATION, AND REPORTING (MER) DATABASE (MER.AMFAR.ORG). LAUNCHED IN DECEMBER 2018, THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. THE DATABASE COMPLEMENTS AMFAR'S PEPFAR DATABASE (COPSDATA.AMFAR.ORG), WHICH HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS.DATA TRANSPARENCYIN OCTOBER 2019, AMFAR PUBLISHED A 20-PAGE REPORT TITLED DATA WATCH: DATA ACCESSIBILITY FROM GLOBAL FUNDERS OF HIV, TB AND MALARIA PROGRAMMING. THE REPORT ASSESSED THE ADEQUACY OF INFORMATION REGARDING WHO IS BEING FUNDED IN A GIVEN COMMUNITY, WHAT THEY HAVE BEEN FUNDED TO DO, AND WHETHER THEY HAVE DELIVERED AS CONTRACTED.AIDS 2020AMFAR'S PUBLIC POLICY OFFICE PARTICIPATED IN THE BIENNIAL INTERNATIONAL AIDS CONFERENCETHE PREMIER GLOBAL MEETING FOR THE HIV FIELDJULY 6-10. DELEGATES CAME TOGETHER VIRTUALLY TO HEAR ABOUT AND DISCUSS THE LATEST HIV RESEARCH FINDINGS AND POLICY ISSUES, AND INTERSECTIONS WITH THE CORONAVIRUS. AMFAR FEATURED PROMINENTLY AT THE CONFERENCE. PUBLIC POLICY DIRECTOR GREG MILLETT DELIVERED AN OPENING PLENARY TALK THAT CONTEXTUALIZED 40 YEARS OF DISPARITIES THROUGHOUT THE HIV PANDEMIC, AND JOINED A LIVE Q&A SESSION WITH DR. LINDA-GAIL BEKKER OF THE DESMOND TUTU HIV CENTRE AT THE UNIVERSITY OF CAPE TOWN, FORMER PRESIDENT OF THE INTERNATIONAL AIDS SOCIETY. 1776060 0 0 21709087 1 1 0 1 0 0 0 1 0 1 1 0 0 0 1 1 1 0 0 1 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 135 0 1 90 1 0 1 TH 0 0 0 1 1 0 0 0 0 0 0 X 13 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA DC FL GA HI IL KS KY MA MD MI MN MS NC NH NJ NM NY OK OR PA RI SC TN TX UT VA WI WV X X BRADLEY JENSEN 2128061703 120 WALL STREET 13TH FLOOR NEW YORK NY 100053908 KEVIN FROST CHIEF EXECUTIVE OFFICER 40.00 X 508136 0 98045 BRADLEY JENSEN ASSISTANT TREASURER/CFO 40.00 X 267796 0 65017 ANNETTE SOHN VICE PRESIDENT, TREAT ASIA 40.00 X 278307 0 25912 ANNMARIE SHANNAHAN VICE PRESIDENT, PUBLIC INF 40.00 X 240920 0 62670 ERIC MUSCATELL VICE PRESIDENT OF DEVELOPM 40.00 X 250840 0 35651 JONATHAN KEY DIRECTOR, PHILANTHROPY 40.00 X 197499 0 59816 ANDREW MCINNESS DIRECTOR, PUBLICATIONS 40.00 X 173900 0 71446 ROWENA JOHNSTON ASST SEC, VP, RESEARCH 40.00 X 211288 0 34033 GREGORIO MILLET VICE PRESIDENT, PUBLIC POL 40.00 X 185938 0 59043 SEBASTIAN GHEITH ASSOCIATE COUNSEL 40.00 X 172174 0 71440 ANTHONY ANCONA VICE PRESIDENT, HUMAN RESO 40.00 X 201830 0 35308 BENNAH SERFATY SENIOR DIRECTOR OF COMMUNICATIONS 40.00 X 137249 0 68882 EDWARD DONNELLY ASST TREASURER, CONTROLLER 40.00 X 169326 0 29876 T RYAN GREENWALT CO-CHAIR 1.00 X X 0 0 0 KEVIN MCCLATCHY CO-CHAIR (AS OF 07/2020) 1.00 X X 0 0 0 BILL ROEDY CHAIRMAN OF THE BOARD (THRU 08/2020)/ NON-VOTING 1.00 X X 0 0 0 CINDY RACHOFSKY VICE CHAIRMAN (THRU 08/2020) 1.00 X X 0 0 0 RAYMOND F SCHINAZI PHD TREASURER 1.00 X X 0 0 0 JAY ELLIS SECRETARY 1.00 X X 0 0 0 ARLEN H ANDERSON SECRETARY (THRU 10/2019) 1.00 X 0 0 0 DANIELLE ALEXANDRA TRUSTEE (AS OF 02/2020) 1.00 X 0 0 0 DAVID BOHNETT TRUSTEE 1.00 X 0 0 0 ZEV BRAUN TRUSTEE (NON-VOTING) (THRU 10/2019) 1.00 X 0 0 0 DONALD DYE TRUSTEE (AS OF 02/2020) 1.00 X 0 0 0 AILEEN GETTY TRUSTEE 1.00 X 0 0 0 GLENN ISAACSON TRUSTEE (AS OF 02/2020) 1.00 X 0 0 0 MICHAEL LORBER TRUSTEE (AS OF 02/2020) 1.00 X 0 0 0 MICHELE V MCNEILL PHARMD TRUSTEE (NON-VOTING) 1.00 X 0 0 0 EDWARD MILSTEIN TRUSTEE (THRU 02/2020) 1.00 X 0 0 0 ALAN D SCHWARTZ TRUSTEE (NON-VOTING) 1.00 X 0 0 0 JEFFREY SCHOENFELD TRUSTEE (AS OF 02/2020) 1.00 X 0 0 0 MARIO STEVENSON TRUSTEE 1.00 X 0 0 0 PHILL WILSON TRUSTEE 1.00 X 0 0 0 2995203 0 717139 25 0 1 0 AAB PRODUCTION INC 64 ALLEN ROAD 5TH FLOOR NEW YORK NY 10002 EVENTS PRODUCTION 505548 JOSH WOODS PRODUCTION 39 WEST 14TH STREET SUITE 504 NEW YORK NY 10011 EVENTS PRODUCTION 335400 TODD EVENT DESIGN 1174 QUAKER STREET DALLAS TX 75207 EVENTS PRODUCTION 236361 SANKY COMMUNICATIONS INC 599 11TH AVENUE 6TH FLOOR NEW YORK NY 10036 DIRECT MAIL/RESPONSE CONSULTANTS 160477 EIDOLON COMMUNICATIONS 15 MAIDEN LANE SUITE 1401 NEW YORK NY 10038 DIRECT MAIL/RESPONSE CONSULTANTS 154503 10 79973 9245331 6657827 5647355 22526 21630486 1224373 1224373 28280 28280 21563532 19594414 1969118 1969118 1969118 836855 9245331 4359161 -3522306 -3522306 18379 8887 9492 9492 LIST RENTAL 900099 2201 2201 STORE SALES 900099 701 701 MISCELLANEOUS 900099 165 165 3067 21342510 0 0 -287976 X 3531803 3531803 2365423 2365423 2624529 1869866 331032 423631 6074492 4032888 699787 1341817 389601 255075 46151 88375 1780600 1171729 251838 357033 523219 334407 66733 122079 83220 78616 4582 22 186888 186888 62055 62055 469617 469617 248715 248715 791588 490945 23629 277014 133904 77572 558 55774 370227 280554 6447 83226 222867 156384 27314 39169 1647091 1125249 200362 321480 477048 164056 1343 311649 420724 410352 4911 5461 6556 4573 815 1168 356670 248782 44323 63565 346063 241384 43005 61674 PROGRAM MATERIALS 2850047 2847947 2100 PROGRAM TECHNICAL SUPPO 762156 762156 BAD DEBT EXPENSE 754768 526461 93794 134513 PRINTING 286696 118152 318 168226 1075329 552658 321604 201067 28841896 21709087 2606249 4526560 X 358748 106092 0 252656 6826913 3725042 1423450 1607204 867952 639936 6339168 3839668 413307 493291 2003877 1159569 7777163 4851332 2800812 2925831 42758997 39141898 722627 1207079 64157103 54739518 2769299 2489524 2086068 1052816 7947789 6138184 1869386 3413100 14672542 13093624 X 45254909 37674119 4229652 3971775 49484561 41645894 64157103 54739518 -7499386 -339281 0 X 0 1 X 1 1 1 X 58810206 50842378 42784390 40275703 21630486 214343163 58810206 50842378 42784390 40275703 21630486 214343163 214343163 1316372 1354513 1590672 1538331 1252653 7052541 2246081 1819001 2097498 1822760 858301 8843641 230239345 230134699 0.93100 0.93420 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2015 AMOUNT: $ 796. 2016 AMOUNT: $ 3,788. 2017 AMOUNT: $ 396. 2018 AMOUNT: $ 1,267. 2019 AMOUNT: $ 165. LIST RENTALS - 2015 AMOUNT: $ 9,117. 2016 AMOUNT: $ 3,691. 2017 AMOUNT: $ 2,793. 2018 AMOUNT: $ 170. 2019 AMOUNT: $ 2,201. INVENTORY - 2015 AMOUNT: $ 169,839. 2016 AMOUNT: $ 13,222. 2017 AMOUNT: $ 48,094. 2018 AMOUNT: $ 25,294. 2019 AMOUNT: $ 18,379. SPECIAL EVENTS - 2015 AMOUNT: $ 2,065,725. 2016 AMOUNT: $ 1,797,050. 2017 AMOUNT: $ 2,043,540. 2018 AMOUNT: $ 1,794,170. 2019 AMOUNT: $ 836,855. STORE SALES - 2015 AMOUNT: $ 604. 2016 AMOUNT: $ 1,250. 2017 AMOUNT: $ 2,675. 2018 AMOUNT: $ 1,859. 2019 AMOUNT: $ 701. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 250802 250802 0 PART II-B, LINE 1: THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. THE FOUNDATION ENGAGED AN INDEPENDENT CONSULTANT TO ENGAGE IN LOBBYING ACTIVITIES ON ITS BEHALF. FEES PAID TO THIS CONSULTANT TOTALED $62,055 IN THE FISCAL YEAR ENDING SEPTEMBER 30, 2020. 548101 X DONATED ITEMS, INVENTORY ETC. 1 701368 7933 22435 731736 684111 6750 10507 701368 593133 4100 86877 684110 541231 5950 45952 593133 493036 7293 40902 541231 0.00000 0.52920 0.47080 0 0 2542490 1590995 951495 307521 304697 2824 4927152 2955640 1971512 2925831 LONG TERM LEASE LIABILITY 1446603 SEC. 457 RETIREMENT LIABILITY 323133 PAYCHECK PROTECTION PRGM LOAN 1643364 3413100 X 20793590 -339279 39074 -300205 21093795 248715 248715 21342510 28632255 39074 39074 28593181 248715 248715 28841896 PART III, LINE 4: COLLECTIONS OF ART, HISTORICAL TREASURES, OR OTHER SIMILIAR ASSETS AMFAR HOLDS VARIOUS ITEMS OF JEWELRY, PHOTOGRAPHS AND OTHER ITEMS OF ARTISTIC VALUE THAT HAVE BEEN DONATED TO THE ORGANIZATION FOR SALE AT SPECIAL EVENTS. THE ORGANIZATION HAS MAINTAINED THESE ITEMS IN INVENTORY FOR A FEW YEARS AND IS IN THE PROCESS OF SELLING THEM. PART V, LINE 4: ENDOWMENTS AMFAR'S ENDOWNMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. PART X, LINE 2: FIN 48 - INCOME TAXES AMFAR FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND GUIDANCE ON MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. AMFAR IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE CODE. AMFAR HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT WAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. AMFAR HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING N/A 1538762 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING N/A 637320 NORTH AMERICA 0 0 GRANTMAKING N/A 52428 SOUTH AMERICA 0 0 GRANTMAKING N/A 36773 SOUTH ASIA 0 0 GRANTMAKING N/A 62787 SUB-SAHARAN AFRICA 0 0 GRANTMAKING N/A 37353 EAST ASIA AND THE PACIFIC 1 13 PROGRAM SERVICES THERAPEUTICS RESEARCH, TRAINING 1827595 EAST ASIA AND THE PACIFIC 0 0 FUNDRAISING N/A 409714 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING N/A 444195 SOUTH AMERICA 0 0 FUNDRAISING N/A 232436 1 13 0 0 1 13 4602732 676631 5279363 EAST ASIA AND THE PACIFIC BASIC RESEARCH 124981 WIRE EAST ASIA AND THE PACIFIC BASIC RESEARCH 12414 WIRE EAST ASIA AND THE PACIFIC BASIC RESEARCH 12500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 8400 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7998 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 20860 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 9754 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 10238 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 10648 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 19983 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 13650 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 15250 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 11244 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 21252 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 16400 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 22236 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 22578 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 21564 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 21578 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 23374 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 20848 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 19650 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 16226 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 23108 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 21356 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 21228 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 79172 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 100865 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 6000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 5850 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 6900 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 263575 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 171054 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 60354 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 24992 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7495 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 15000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 15000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 7500 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 20000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 5648 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 10000 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 14924 WIRE EAST ASIA AND THE PACIFIC TREAT ASIA 14013 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 628320 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 9000 WIRE NORTH AMERICA BASIC RESEARCH 52428 WIRE SOUTH AMERICA BASIC RESEARCH 36773 WIRE SOUTH ASIA TREAT ASIA 18850 WIRE SOUTH ASIA TREAT ASIA 18085 WIRE SOUTH ASIA TREAT ASIA 7500 WIRE SOUTH ASIA TREAT ASIA 7498 WIRE SOUTH ASIA TREAT ASIA 8500 WIRE SUB-SAHARAN AFRICA BASIC RESEARCH 12501 WIRE SUB-SAHARAN AFRICA BASIC RESEARCH 12351 WIRE SUB-SAHARAN AFRICA BASIC RESEARCH 12501 WIRE 71 0 0 0 0 0 0 PART I, LINE 2: FOREIGN ACTIVITIES INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE. PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH SITES REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORTING ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES PART I, LINE 3, COLUMN D THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S. AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S. ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 71 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S. CHARITIES. PART III ACCOUNTING METHOD: X X X X X X 1 JOSH WOODS PRODUCTION 245 W 29TH STREET NEW YORK NY 10001 SPECIAL EVENT PRODUCTION 0 1947108 195100 1752008 AAB PRODUCTIONS 64 ALLEN ST NEW YORK NY 10002 SPECIAL EVENT PRODUCTION 0 1797126 248394 1548732 SANKY COMMUNICATIONS INC 599 11TH AVE NEW YORK NY 10036 DIRECT MAIL DIRECT RESPONSE CONSULTING 0 1100403 326775 773628 4844637 770269 4074368 AK AL AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VA WA WV WI DALLAS 4781288 4579183 202105 313834 223391 119197 952089 NY GALA 1272758 1006258 266500 23601 235133 82192 332434 18 4028140 3659890 368250 426167 168750 388178 1094195 10082186 9245331 836855 763602 627274 589567 2378718 4359161 -3522306 SCHEDULE G, PART I, LINE 2B, COLUMN (V) THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $469,617 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2020. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $770,269. OF THAT $770,269, ONLY $469,617 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $300,652 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN PART VII). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE. 1 THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 48109 386006309 501(C)(3) 38912 BASIC RESEARCH THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 84311 BASIC RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 88927 BASIC RESEARCH MAYO CLINIC COLLEGE OF MEDICINE 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 21429 BASIC RESEARCH OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 97239 931176109 501(C)(3) 17853 BASIC RESEARCH UNIVERSITY OF MARYLAND AT BALTIMORE 725 LOMBARD STREET ROOM S615 BALTIMORE MD 21201 526002033 501(C)(3) 15000 BASIC RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 17857 BASIC RESEARCH WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 9703 BASIC RESEARCH THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19104 236434390 501(C)(3) 27082 BASIC RESEARCH THE BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 20832 BASIC RESEARCH HARVARD PILGRIM HEALTH CARE INSTITUTE 93 WORCESTER STREET STE 100 WELLESLEY MA 02481 042452600 501(C)(3) 33270 BASIC RESEARCH NATIONAL INSTITUTES OF HEALTH 9650 ROCKVILLE PIKE BETHESDA MD 208143999 521986675 501(C)(3) 31250 BASIC RESEARCH OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 97239 931176109 501(C)(3) 37500 BASIC RESEARCH YALE UNIVERSITY 266 WHITNEY AVE NEW HAVEN CT 06511 060646973 501(C)(3) 37500 BASIC RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94143 946036493 501(C)(3) 1759191 RESEARCH REGENTS OF THE UNIVERSITY OF MINNESOTA SPONSORED PROJECTS ADMINISTRATION 200 OAK STREET SE SUITE 450 MINNEAPOLIS MN 554552070 416007513 501(C)(3) 121650 RESEARCH JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 97854 RESEARCH UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE BOX 359472 SEATTLE WA 981959472 916001537 501(C)(3) 296609 RESEARCH THE BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 278107 RESEARCH COLUMBIA UNIVERSITY 630 WEST 168TH ST BOX 49 NEW YORK NY 10032 135598093 501(C)(3) 23820 TREAT ASIA JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 233489 TREAT ASIA NEW HOPE FOR CAMBODIAN CHILDREN PO BOX 690597 KILLEEN TX 76549 205301015 501(C)(3) 20024 TREAT ASIA 22 PART I, LINE 2: AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE-YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT OR FELLOWSHIPS. IN CERTAIN CASES, THE ACTUAL AMOUNTS PAID UNDER GRANTS AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE SUBAWARD TERMS. X X X X 0 1 0 0 0 0 0 0 0 KEVIN FROST CHIEF EXECUTIVE OFFICER 445388 0 0 0 62748 0 38600 0 59445 0 606181 0 0 0 BRADLEY JENSEN ASSISTANT TREASURER/CFO 267796 0 0 0 0 0 19486 0 45531 0 332813 0 0 0 ANNETTE SOHN VICE PRESIDENT, TREAT ASIA 278307 0 0 0 0 0 18077 0 7835 0 304219 0 0 0 ANNMARIE SHANNAHAN VICE PRESIDENT, PUBLIC INF 240920 0 0 0 0 0 17139 0 45531 0 303590 0 0 0 ERIC MUSCATELL VICE PRESIDENT OF DEVELOPM 250840 0 0 0 0 0 16474 0 19177 0 286491 0 0 0 JONATHAN KEY DIRECTOR, PHILANTHROPY 197499 0 0 0 0 0 14285 0 45531 0 257315 0 0 0 ANDREW MCINNESS DIRECTOR, PUBLICATIONS 173900 0 0 0 0 0 12501 0 58945 0 245346 0 0 0 ROWENA JOHNSTON ASST SEC, VP, RESEARCH 211288 0 0 0 0 0 14856 0 19177 0 245321 0 0 0 GREGORIO MILLET VICE PRESIDENT, PUBLIC POL 185938 0 0 0 0 0 14391 0 44652 0 244981 0 0 0 SEBASTIAN GHEITH ASSOCIATE COUNSEL 172174 0 0 0 0 0 12495 0 58945 0 243614 0 0 0 ANTHONY ANCONA VICE PRESIDENT, HUMAN RESO 201830 0 0 0 0 0 13842 0 21466 0 237138 0 0 0 BENNAH SERFATY SENIOR DIRECTOR OF COMMUNICATIONS 137249 0 0 0 0 0 9937 0 58945 0 206131 0 0 0 EDWARD DONNELLY ASST TREASURER, CONTROLLER 169326 0 0 0 0 0 12310 0 17566 0 199202 0 0 0 PART I, LINE 4B COMPENSATION CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2019, AMFAR CONTRIBUTED $62,748 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2019 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $62,748. IMPACT OF COVID-19 THE EMERGENCE AND RAPID SPREAD OF COVID-19 ACROSS THE UNITED STATES IN EARLY 2020 HAS IMPACTED WORLDWIDE ECONOMIC ACTIVITY AND FINANCIAL MARKETS, HAD AN IMMEDIATE, SUBSTANTIAL AND SUSTAINED IMPACT ON AMFAR'S OPERATIONAL AND FUNDRAISING CAPACITY. WITH FUNDRAISING PERFORMANCE TIED IN LARGE PART TO AMFAR'S ABILITY TO ORCHESTRATE AND EXECUTE BENEFIT GALAS ACROSS THE U.S. AND AROUND THE WORLD, THE CORONAVIRUS LOCKDOWN AND STRICT LIMITATIONS ON INTERNATIONAL TRAVEL AND CONGREGATE EVENTS BROUGHT THIS REVENUE STREAM TO A HALT ALMOST OVERNIGHT. SINCE THE SPRING OF 2020, ALL LIVE FUNDRAISING EVENTS HAVE BEEN SUSPENDED, ALL NONESSENTIAL EXPENSES HAVE BEEN ELIMINATED, AND AMFAR HAS BEEN DEPENDENT ON ITS FINANCIAL RESERVES. THE FOUNDATION REMAINS IN A HOLDING PATTERN UNTIL SUCH TIME AS WIDESPREAD VACCINE DISTRIBUTION HAS CONTROLLED THE PANDEMIC TO THE EXTENT THAT UNFETTERED INTERNATIONAL TRAVEL AND LARGE GATHERINGS OF PEOPLE CAN RESUME. MANAGEMENT HAS CONSIDERED THE CONSEQUENCES OF COVID AND DETERMINED THAT THERE IS NO CURRENT MATERIAL UNCERTAINTY IDENTIFIED THAT WOULD AFFECT ITS ABILITY TO CONTINUE ITS MISSION TO END THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. HOWEVER, THERE IS SIGNIFICANT UNCERTAINTY AROUND THE BREADTH AND DURATION OF BUSINESS DISRUPTIONS RELATED TO COVID, AS WELL AS ITS IMPACT ON THE U.S. AND INTERNATIONAL ECONOMIES AND, AS SUCH, THE FOUNDATION IS UNABLE TO DETERMINE IF IT WILL HAVE A FUTURE MATERIAL NEGATIVE IMPACT ON ITS OPERATIONS OR FINANCIAL CONDITION. PAYCHECK PROTECTION PROGRAM LOAN ON MAY 6, 2020, AMFAR WAS GRANTED A LOAN IN AGGREGATE AMOUNT OF $1,643,364 PURSUANT TO THE SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM ("THE PPP") UNDER DIVISION A, TITLE 1 OF THE CARES ACT (THE "PPP LOAN"). THE PPP LOAN, WHICH WAS IN THE FORM OF A NOTE DATED MAY 1, 2020, MATURES ON MAY 6, 2022 AND BEARS INTEREST AT A RATE OF 1% PER ANNUM. THE PPP LOAN MAY BE PREPAID BY AMFAR AT ANY TIME PRIOR TO MATURITY WITH NO REPAYMENT PENALTIES. FUNDS FROM THE PPP LOAN MAY ONLY BE USED FOR CERTAIN COSTS, SUCH AS PAYROLL COSTS AND OCCUPANCY EXPENSES. THE LOAN AND ACCRUED INTEREST ARE FORGIVABLE AS LONG AS THE BORROWER USES THE LOAN PROCEEDS AS DESCRIBED IN THE CARES ACT. AMFAR USED THE ENTIRE PPP LOAN FOR QUALIFYING EXPENSES AS DESCRIBED IN THE CARES ACT AND HAVE INITIATED THE PROCESS OF THE LOAN FORGIVENESS REQUEST ACCORDING TO THE TERMS OF THE PPP LOAN. AMFAR EVALUATED ITS SEPTEMBER 30, 2020 FINANCIAL STATEMENTS FOR SUBSEQUENT EVENTS THROUGH MARCH 4, 2021, THE DATE THE FINANCIAL STATEMENTS WERE AVAILABLE TO BE ISSUED. ON FEBRUARY 19, 2021, AMFAR WAS APPROVED FOR A SECOND PPP LOAN TOTALING $1,677,930. THE PPP LOAN MATURES IN FEBRUARY 2026, AND BEAR INTEREST AT A RATE OF 1% PER ANNUM. THE PPP LOAN MAY BE PREPAID BY AMFAR AT ANY TIME PRIOR TO MATURITY WITH NO PREPAYMENT PENALTIES. FUNDS FROM THE PPP LOAN MAY ONLY BE USED FOR CERTAIN COSTS, SUCH AS PAYROLL COSTS, OCCUPANCY EXPENSES, AND CERTAIN OTHER EXPENSES. FORM 990, PART III, LINE 1 - ORGANIZATION'S MISSION THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: - RESEARCH TO EXPLORE SCIENTIFIC APPROACHES TO HIV PREVENTION, TREATMENT, AND POTENTIAL CURES, AND TO ENHANCE THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV/AIDS; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN DEVELOPING COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; - EDUCATIONAL INITIATIVES TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PUBLISH UPDATES ABOUT THE LATEST MEDICAL, SCIENTIFIC, AND PREVENTION ADVANCES FOR PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC. FORM 990, PART III, LINE 4A: ARCHE (AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION) FOR SEVERAL YEARS, AMFAR'S ARCHE-GT CONSORTIUM HAS BEEN DESIGNING AND FINE-TUNING THREE GENE THERAPY APPROACHES TO CURING HIV THAT COULD BE DELIVERED IN VIVODIRECTLY TO THE PATIENT. ONE APPROACH INVOLVES THE GENERATION OF CHIMERIC ANTIGEN RECEPTOR (CAR) STEM CELLS THAT ARE DESIGNED SPECIFICALLY TO KILL VIRUS-INFECTED CELLS. A SECOND IS TO SPUR LIVER CELLS TO PRODUCE HIV-SPECIFIC ANTIBODIES. THE THIRD IS TO DELIVER AN ENZYME THAT WOULD EDIT THE VIRUS OUT OF INFECTED CELLS. EACH OF THESE THREE TOOLS IS NOW READY TO BE TESTED IN COMBINATION. IN FEBRUARY 2020, DR. HILDEGARD BNING OF HANNOVER MEDICAL SCHOOL, GERMANY, WAS AWARDED $1.65 MILLION FOR A PRECLINICAL STUDY TO TEST THEIR EFFECTIVENESS. THE RESEARCHERS WILL START BY ADMINISTERING THE CAR STEM CELL TREATMENT IN THE FIRST YEAR OF THE TWO-YEAR STUDY. TREATMENT WITH THE OTHER TWO INTERVENTIONS WILL FOLLOW IN THE SECOND YEAR. AT THE END OF THIS PROOF-OF-PRINCIPLE STUDY, RESEARCHERS WILL DETERMINE THE ACTIVITY OF EACH OF THE INTERVENTIONS ALONE AND IN COMBINATION, AND THEIR EFFECT ON THE PERSISTENCE OF THE VIRUS. THIS COMPLEX GENE THERAPY STUDY WILL PROVIDE VITAL SIGNPOSTS INFORMING FURTHER CURATIVE GENE THERAPY STUDIES. MATHILDE KRIM FELLOWSHIPS IN DECEMBER 2019, AMFAR ANNOUNCED THE RECIPIENTS OF THE 2019 MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH: DR. MAOLIN LU OF YALE UNIVERSITY IN NEW HAVEN, CT, AND DR. SHAHEED ABDULHAQQ, OF OREGON HEALTH AND SCIENCE UNIVERSITY IN PORTLAND, OR. THE KRIM FELLOWSHIPS SUPPORT BRIGHT YOUNG SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. COVID-19 GRANTS EXPANDING ITS EFFORTS TO INCLUDE RESEARCH ON THE NOVEL CORONAVIRUS, IN APRIL 2020 AMFAR ESTABLISHED THE AMFAR FUND TO FIGHT COVID-19, ANNOUNCING ITS FIRST COVID GRANTS IN JULY. A COMMON AND OFTEN DEADLY CONSEQUENCE OF ADVANCED COVID-19 DISEASE IS ACUTE KIDNEY INJURY. CELLS IN THE KIDNEY EXPRESS THE ACE2 PROTEIN, WHICH SERVES AS A RECEPTOR FOR THE VIRUS AND MAY UNDERLIE THE KIDNEY DAMAGE. DR. MATTHIAS KRETZLER OF THE UNIVERSITY OF MICHIGAN, ANN ARBOR, WAS AWARDED $155,650 TO USE A CLEVER TECHNIQUE TO UNDERSTAND WHAT HAPPENS IN THE KIDNEY OF THOSE WITH COVID-19. BY COMPARING PATIENTS RECEIVING ANTI-INFLAMMATORY TREATMENT TO THOSE WHO WERE NOT, DR. KRETZLER AIMED TO DEVELOP A TOOL TO PREDICT WHO WOULD MOST BENEFIT FROM THIS KIND OF TREATMENT. A SECOND GRANT OF $192,000 WAS AWARDED TO DR. DANIEL KAUFMANN OF THE UNIVERSITY OF MONTREAL FOR A STUDY OF ANTIBODY RESPONSES TO COVID-19. DR. KAUFMANN WAS ABLE TO TAP INTO THE QUEBEC COVID-19 BIOBANK, ESTABLISHED AT THE BEGINNING OF THE PANDEMIC TO COLLECT BIOLOGICAL SAMPLES FROM PATIENTS ADMITTED TO THE HOSPITAL. THESE BANKED SAMPLES, COLLECTED FROM THE TIME OF ADMISSION THROUGH SEVERAL MONTHS OF FOLLOW-UP, ALLOWED DR. KAUFMANN AND HIS TEAM TO ANSWER WHY SOME PEOPLE DEVELOP ANTIBODIES AND OTHERS DO NOT, HOW WE CAN PREDICT WHETHER THOSE ANTIBODIES PROTECT AGAINST REINFECTION, AND HOW LONG THE PROTECTION WILL LAST. THE RESULTS WILL PROVIDE VALUABLE INFORMATION TO INFORM THE DESIGN OF VACCINES. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2020, 80 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: SEEING IS BELIEVING: NUCLEAR IMAGING OF HIV PERSISTENCE A KEY BARRIER TO HIV ERADICATION IS THE PRESENCE OF LATENTLY INFECTED RESERVOIR CELLS THAT PERSIST DESPITE ART. THE ABILITY TO FIND HOST TISSUE CELLS THAT ENABLE HIV TO EVADE DISCOVERY BY ROUTINE SAMPLING MAY HELP RESEARCHERS TO IDENTIFY WHICH TISSUES ARE RESPONSIBLE FOR HIV RESURGENCE FOLLOWING TREATMENT INTERRUPTION AS PART OF A CURE INTERVENTION. DR. TIMOTHY HENRICH OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH REPORTED ON THE DEVELOPMENT OF A NEW TECHNIQUE USING PET SCANNING TO VISUALIZE THE PLACES WHERE HIV RESIDES. IN THE JOURNAL FRONTIERS IN IMMUNOLOGY, DR. HENRICH AND COLLEAGUES OUTLINED A VALUABLE TECHNIQUE USING THE ONLY EXPLORER SCANNER CURRENTLY OPERATIONAL IN THE U.S. THE MACHINE IS ABLE TO PRODUCE IMAGES THAT ARE APPROXIMATELY 40 TIMES MORE SENSITIVE THAN CURRENT TECHNOLOGY IN A FRACTION OF THE TIME. ATTACKING LATENT HIV WITH CONVERTIBLE CAR-T CELLS, A HIGHLY ADAPTABLE KILLING PLATFORM IN THE JOURNAL CELL, MEMBERS OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH REPORTED THE DEVELOPMENT OF A NEW TYPE OF CAR T CELLONE THAT CAN KEEP UP WITH HIV'S EVER MUTATING ENVELOPE. CONVERTIBLE CAR T CELLS CAN TARGET MULTIPLE STRAINS OF HIV WITHOUT THE NEED TO MANUFACTURE AS MANY DIFFERENT CAR T CELLS AS THERE ARE STRAINS. HARNESSING THE ABILITY OF THIS NEW PLATFORM TO SELECTIVELY KILL HIV-INFECTED CELLS, RESEARCHERS MAY BE ABLE TO DEVELOP MORE EFFECTIVE CURE STRATEGIES IN WHICH LATENCY-REVERSING AGENTS REACTIVATE LATENT HIV. HIV CURE SUMMIT IN NOVEMBER 2019, AMFAR HELD ITS SIXTH ANNUAL HIV CURE SUMMIT AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF), WHERE THE AMFAR INSTITUTE FOR HIV CURE RESEARCH IS BASED. LEADING AMFAR-FUNDED CURE RESEARCHERS DETAILED THEIR PROGRESS AND DISCUSSED THE SCIENTIFIC CHALLENGES THAT CONTINUE TO STAND IN THE WAY OF A CURE. DR. RACHEL RUTISHAUSER, FOR EXAMPLE, OUTLINED A PIONEERING CLINICAL TRIAL AT THE INSTITUTE THAT WILL TEST A COMBINATION APPROACH TO CURING HIV. DR. ROWENA JOHNSTON, AMFAR VICE PRESIDENT AND DIRECTOR OF RESEARCH, DISCUSSED "SOCIETIES OF RESEARCH," DISPLAYING A VISUALIZATION TOOL TO SHOW HOW IN RECENT YEARS HIV RESEARCHERS ARE COLLABORATING MORE THAN EVER BEFORE. SPEAKING WITH DR. JOHNSTON, LOREEN WILLENBERG, THE "SAN FRANCISCO PATIENT," SHARED HER INSPIRING PERSONAL STORY, FROM HER HIV DIAGNOSIS IN 1992 TO RECOGNITION BY HER DOCTORS THAT SHE WAS SOMEHOW ABLE TO MAINTAIN UNDETECTABLE VIRAL LEVELS WITHOUT EVER TAKING ART, TO BEING AN INVALUABLE PARTICIPANT IN HIV STUDIES FOR OVER A DECADE. DISCUSSING POST-TREATMENT CONTROL OF HIV, DRS. PETER HUNT OF UCSF AND MARCELLA FLORES OF AMFAR OUTLINED EFFORTS TO STUDY THE RARE INDIVIDUALS WHO ARE ABLE TO NATURALLY CONTROL THEIR VIRUS AFTER STOPPING ART. A BETTER UNDERSTANDING OF HOW THESE INDIVIDUALS ARE ABLE TO DO SO COULD HELP RESEARCHERS INDUCE POST-TREATMENT CONTROL IN OTHER PEOPLE LIVING WITH HIV. THE SUMMIT ALSO FEATURED A RANGE OF PERSPECTIVES FROM MEMBERS OF THE COMMUNITY ADVISORY BOARD FOR THE AMFAR INSTITUTE AND OTHER COMMUNITY LEADERS. FORM 990, PART III, LINE 4E OTHER PROGRAM SERVICE ACCOMPLISHMENTS AMFAR'S DEPUTY DIRECTOR OF PUBLIC POLICY BRIAN HONERMANN PRESENTED AT A VIRTUAL COMMUNITY WORKSHOP THAT FOCUSED ON THE EFFECTIVE USE OF DATA TOOLS TO DRIVE IMPACTFUL CHANGE IN THE HIV RESPONSE. AND POLICY ASSOCIATE JENNIFER SHERWOOD GAVE A SYMPOSIUM TALK ON WHETHER CURRENT APPROACHES TO COLLECTING DATA CAPTURE THE FULL IMPACT OF HIV ON WOMEN. THE CONFERENCE FEATURED MANY TALKS ON THE INTERSECTION OF HIV AND COVID-19. GREG MILLETT JOINED MERCK VICE PRESIDENT OF SOCIAL INNOVATION CARMEN VILLAR FOR A "FIRESIDE CHAT" TO DISCUSS A PAPER MILLETT CO-AUTHORED ASSESSING THE DIFFERENTIAL IMPACTS OF COVID-19 ON BLACK COMMUNITIES. MILLETT ALSO JOINED CHRIS COLLINS OF FRIENDS OF THE GLOBAL FIGHT AND OTHERS IN A SESSION TITLED HOW DID THEY DO IT? WHAT SUCCESSFUL COMMUNITIES CAN TEACH ALL OF US ABOUT MAKING DRAMATIC PROGRESS AGAINST HIV EPIDEMICS AND WHAT THIS MEANS IN THE AGE OF COVID. THE SESSION WAS A ONE-YEAR FOLLOW-UP TO A REPORT CO-AUTHORED BY AMFAR, AVAC AND FRIENDS OF THE GLOBAL FIGHT TITLED TRANSLATING PROGRESS INTO SUCCESS TO END THE AIDS EPIDEMIC. THE GMT INITIATIVE THE TWO IMPLEMENTATION SCIENCE STUDIES BEING SUPPORTED BY AMFAR'S GMT INITIATIVE CAME TO AN END IN 2019, BRINGING THE INITIATIVE TO A CLOSE. THE THREE-YEAR PROJECTS, IN MYANMAR AND THAILAND, WERE AIMED AT DETERMINING THE MOST EFFECTIVE WAYS OF ENGAGING GAY MEN, OTHER MEN WHO HAVE SEX WITH MEN (MSM), AND TRANSGENDER INDIVIDUALS (COLLECTIVELY, GMT) AT RISK OF INFECTION OR ALREADY LIVING WITH HIV. THE GOAL WAS TO HELP THOSE WHO WERE HIV-NEGATIVE STAY UNINFECTED, AND HELP HIV-POSITIVE INDIVIDUALS TO BEGIN AND REMAIN ON TREATMENT. A THIRD PROJECT, IN PERU, ENDED IN 2018. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. FORM 990, PART VI, SECTION B, LINE 15 AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN NOVEMBER OF 2019 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. FORM 990, PART VI, SECTION C, LINE 19 AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. PART IX, LINES 1 & 3 THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.